A novel treatment for septic shock has been developed by Prof. Danièle BENSOUSSAN, Head of the Cell Therapy and Tissue Bank Unit, Placental Blood Bank (UTCT) at the Nancy University Hospital and professor-researcher at the IMoPA laboratory (CNRS-University of Lorraine). Accompanied by SATT SAYENS, this development led to the creation of the start-up company StemInov, co-founded by Julie HUTIN, a centralist, with the support of the Lorraine Incubator from the outset.
The drug is based on the use of mesenchymal stem cells derived from the umbilical cord (Wharton's jelly MSCs). These cells have very promising properties for treating inflammatory diseases. Endowed with a modulable effect to regulate inflammation, they are able to target and migrate towards damaged tissues in order to exert a repair action and also exert an anti-bacterial activity: different properties of interest in a pathology such as septic shock.
SATT SAYENS supported the development of this biomedicine with a dedicated maturation program including laboratory tests and leading to the filing of a patent.